Outcomes in ankylosing spondylitis: What makes the assessment of treatment effects in ankylosing spondylitis different?

Annals of the Rheumatic Diseases

Volumn 65, Issue SUPPL. 3, 2006, Pages

  Ward, M M ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE RECEPTOR ANTAGONIST; TUMOR NECROSIS FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC TEST; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; HEALTH CARE COST; HUMAN; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICAL DISABILITY; PRIORITY JOURNAL; SPINAL CORD LESION; SPINE FUSION; SYMPTOMATOLOGY; WORK DISABILITY;

BIOLOGICAL MARKERS; DISABILITY EVALUATION; HEALTH STATUS INDICATORS; HUMANS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 33750379321     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.058461     Document Type: Conference Paper

References (52)

1. Ward MM. Assessment of health outcomes. In: Harris ED Jr, ed. Kelley's Textbook of Rheumatology, 7th edn. Philadelphia: Elsevier Science, 2005:435-46.
2. World Health Organization. ICF: International Classification of Functioning, Disability, and Health. Introduction. Geneva: World Health Organization, 2001. Available at: www3.who.int/icf/icftemplate.cfm (accessed 5 December 2001).
3. van der Heidje D, van der Linden S, Bellamy N, Calin A, Dougados M, Khan MA. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol 1999;26:945-7.
4. van der Heidje D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessment in Ankylosing Spondylitis. J Rheumatol 1999;26:951-4.
5. Rudawleit M, Hilgert E, Haibel H, Sieper J. Evaluation of a spinal pain score performed by the rheumatologist in ankylosing spondylitis [abstract]. European League Against Rheumatism Scientific Meeting, 12-15 June 2003, Lisbon, Portugal.
6. Heikkila S, Viitanen JV, Kautiainen H, Kauppi M. Sensitivity to change of mobility tests: effect of short term intensive physiotherapy and exercise on spinal, hip, and shoulder measurements in spondyloarthropathy. J Rheumatol 2000;27:1251-6.
7. Haywood KL, Garratt AM, Jordan K, Dziedzic K, Dawes PT. Spinal mobility in ankylosing spondylitis: reliability, validity, and responsiveness. Rheumatology 2004;43:750-7.
8. Jauregui E, Conner-Spady B, Russell AS, Maksymowych WP. Clinimetric evaluation of the Bath Ankylosing Spondylitis Metrology Index in a controlled trial of pamidronate therapy. J Rheumatol 2004;31:2422-8.
9. Wanders AJ, Gorman JD, Davis JC, Landewe RB, van der Heijde DM. Responsiveness and discriminative capacity of the Assessments in Ankylosing Spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. Arthritis Rheum 2004;51:1-8.
10. Ward MM, Kuzis S. Ceiling effects and the Schober test. J Rheumatol 2003;30:2732-3.
11. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
12. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
13. Maksymowych WP, Jauregui E, Spady B, Russell AS. The Bath Ankylosing Spondylitis Disease Activity Index: Lack of discriminant ability between AS and mechanical low back pain [abstract]. European League Against Rheumatism Scientific Meeting, 12-15 June 2003, Lisbon, Portugal.
14. de Vlam K, Bokken A. BASDAI is unable to discriminate between inflammatory low back pain and mechanical low back pain [abstract]. Ann Rheum Dis 2005;64(suppl III):335.
15. Taylor AL, Balakrishnan C, Calin A. Centile reference charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis. Arthritis Rheum 1998;41:1119-25.
16. Barkham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan AM, et al. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology 2005;44:1277-81.
17. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. Relative value of the erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26:980-4.
18. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
19. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002;359:1187-93.
20. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
21. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomized clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.
22. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
23. Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'connor P, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 2005;64:1568-75.
24. Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006;54:678-81.
25. Ribbens C, Martin y Porras M, Franchimont N, Franchimont N, Kaiser MJ, Jaspar JM, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002;61:161-6.
26. Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29:959-65.
27. Vandooren B, Kruithof E, Yu DT, Rihl M, Gu J, De Rycke L, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondyloarthropathy. Arthritis Rheum 2004;50:2942-53.
28. Yang C, Gu J, Rihl M, Baeten D, Huang F, Zhao M, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor I correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004;51:691-9.
29. Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005;32:1911-17.
30. Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology 2006;45:414-20.
31. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
32. Drouart M, Saas P, Billot M, Cedoz JP, Tiberghien P, Wendling D, et al. High serum vascular endothelial growth factor correlates with disease activity of spondyloarthropathies. Clin Exp Immunol 2003;132:158-62.
33. Kim TH, Stone M, Payne U, Zhang X, Ionescu M, Lobanok T, et al. Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. Arthritis Rheum 2005;52:885-91.
34. Yilmaz N, Ozaslan J. Biochemical bone turnover markers in patients with ankylosing spondylitis. Clin Rheumatol 2000;19:92-8.
35. Toussirot E, Ricard-Blum S, Dumoulin G, Cedoz JP, Wendling D. Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology 1999;38:21-7.
36. Marhoffer W, Stracke H, Masoud I, Scheja M, Graef V, Bolten W, et al. Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis 1995;54:556-9.
37. Visvanathan S, Braun J, van der Heijde D, Marini JC, Han J, Gathany T, et al. Effect of infliximab on markers of inflammation and angiogenesis and correlations with improvement in spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis [abstract]. Arthritis Rheum 2005;52(suppl):S279.
38. Park M-C, Lee S-W, Choi S-T, Park Y-B, Lee S-K. Bone and cartilage turnover markers, bone mineral density, and radiographic damage in men with ankylosing spondylitis [abstract]. Arthritis Rheum 2005;52(suppl):S641.
39. Kirshner B, Guyatt G. A methodological framework for assessing health indices. J Chronic Dis 1985;38:27-36.
40. Ward MM. Evaluative laboratory testing. Assessing tests that assess disease activity. Arthritis Rheum 1995;38:1555-63.
41. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
42. Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005;52:1216-23.
43. Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J. Magnetic resonance imaging of the spine and sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 2005;64:1305-10.
44. Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology 2005;44:1525-30.
45. MacKay K, Mack C, Brophy S, Calin A. The Bath Ankylosing Spondylitis Radiology index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 1998;41:2263-70.
46. Spoorenberg A, de Vlam K, van der Linden S, Dougados M, Mielants H, van de Tempel H, et al. Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years. J Rheumatol 2004;31:125-32.
47. Wanders AJ, Landewe RB, Spoorenberg A, Dougodos M, van der Linden S, Mielants H, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 2004;50:2622-32.
48. van der Heijde D, Landewe R, van der Linden S. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis Rheum 2005;52:1979-85.
49. Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-van Molken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
50. Boonen A, Chorus A, Landewe R, van der Heijde D, Miedema H, van der Tempel H, et al. Manual jobs increase the risk of patients with ankylosing spondylitis withdrawing from the labour force, also when adjusted for job related withdrawal in the general population. Ann Rheum Dis 2002;61:658.
51. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
52. Ward MM, Kuzis S. Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol 2001;28:315-21.